Showing session: reset
Regulatory Considerations for Utilizing Liquid Biopsies in Drug and Diagnostic Development
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Chairperson
Pasi A Janne
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Invited Speaker
Abraham Tzou
U.S. Food and Drug Administration, Silver Spring, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Invited Speaker
Suzanne Jenkins
AstraZeneca, Cheshire, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Invited Speaker
Gary J. Kelloff
NCI-DCTD, Rockville, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Invited Speaker
Walter H. Koch
Roche Molecular Systems, Inc., Pleasanton, CA, United States
- Free
- audio + slides
- Some slides withheld
Invited Speaker
Howard Scher
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- audio + slides
- All slides included
Panel Discussion
Pasi A Janne
Dana-Farber Cancer Institute, Boston, MA, United States
Amirali Talasaz
Guardant Health Inc, Redwood City, CA, United States
Gideon Blumenthal
U.S. Food and Drug Administration, Silver Spring, MD, United States
Reena Philip
U.S. Food and Drug Administration, Silver Spring, MD, United States
Abraham Tzou
U.S. Food and Drug Administration, Silver Spring, MD, United States
Suzanne Jenkins
AstraZeneca, Cheshire, United Kingdom
Gary J. Kelloff
NCI-DCTD, Rockville, MD, United States
Walter H. Koch
Roche Molecular Systems, Inc., Pleasanton, CA, United States
Howard Scher
Memorial Sloan Kettering Cancer Center, New York, NY, United States
Phil Stephens
Foundation Medicine, Inc., Cambridge, MA, United States